Thomas Jens Ettrich

33PUBLICATIONS
115CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosisTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jun 10, 2026
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.

|Feb 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience

|Oct 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko

|Mar 28, 2025
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.

Christian Möhring, Moritz Berger, Farsaneh Sadeghlar

|Mar 11, 2025
Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.

Ulrich Güller, Stefanie Hayoz, Daniel Horber

|Nov 14, 2024
Organoid-based precision medicine in pancreatic cancer.

Alica K Beutel, Menar Ekizce, Thomas J Ettrich

Pageof 6

Frequent Collaborators

6 joint publications

Angelika Kestler

5 joint publications

Sylvie Lorenzen

5 joint publications

Lukas Perkhofer

3 joint publications

Maria Loose